🚀 VC round data is live in beta, check it out!
Prestige Biologics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Prestige Biologics and similar public comparables like AN2 Therapeutics, Oncolytics Biotech, Equillium, Immunic and more.
Prestige Biologics Overview
About Prestige Biologics
Prestige Biologics Co Ltd is a CDMO-dedicated company that provides solutions of development and manufacturing tasks throughout the stages from the research/development, engineering, clinical production, commercial production, clinical support, and IND & BLA filing of biopharmaceutical products. Its product candidate includes HD201 (Herceptin Biosimilar).
Founded
2015
HQ
Employees
N/A
Website
Financials (FY)
EV
$186M
Prestige Biologics Financials
Prestige Biologics reported last fiscal year revenue of $8M and negative EBITDA of ($4M).
In the same fiscal year, Prestige Biologics generated ($11M) in gross profit, ($4M) in EBITDA losses, and had net loss of ($19M).
Prestige Biologics P&L
In the most recent fiscal year, Prestige Biologics reported revenue of $8M and EBITDA of ($4M).
Prestige Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $8M | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($11M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (125%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($4M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (45%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (269%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($19M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (219%) | XXX | XXX | XXX |
| Net Debt | — | — | $61M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Prestige Biologics Stock Performance
Prestige Biologics has current market cap of $130M, and enterprise value of $186M.
Market Cap Evolution
Prestige Biologics' stock price is $1.67.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $186M | $130M | 0.8% | XXX | XXX | XXX | $-0.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPrestige Biologics Valuation Multiples
Prestige Biologics trades at 21.9x EV/Revenue multiple, and (48.7x) EV/EBITDA.
Prestige Biologics Financial Valuation Multiples
As of April 18, 2026, Prestige Biologics has market cap of $130M and EV of $186M.
Equity research analysts estimate Prestige Biologics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Prestige Biologics has a P/E ratio of (7.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $130M | XXX | $130M | XXX | XXX | XXX |
| EV (current) | $186M | XXX | $186M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 21.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (48.7x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (8.2x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (17.5x) | XXX | XXX | XXX |
| P/E | — | XXX | (7.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (11.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Prestige Biologics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Prestige Biologics Margins & Growth Rates
Prestige Biologics' revenue in the last fiscal year grew by 478%.
Prestige Biologics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 478% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (45%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (11%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 144% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Prestige Biologics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Prestige Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| AN2 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncolytics Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Equillium | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunic | XXX | XXX | XXX | XXX | XXX | XXX |
| Vaxcell-Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prestige Biologics M&A Activity
Prestige Biologics acquired XXX companies to date.
Last acquisition by Prestige Biologics was on XXXXXXXX, XXXXX. Prestige Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Prestige Biologics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPrestige Biologics Investment Activity
Prestige Biologics invested in XXX companies to date.
Prestige Biologics made its latest investment on XXXXXXXX, XXXXX. Prestige Biologics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Prestige Biologics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Prestige Biologics
| When was Prestige Biologics founded? | Prestige Biologics was founded in 2015. |
| Where is Prestige Biologics headquartered? | Prestige Biologics is headquartered in South Korea. |
| Is Prestige Biologics publicly listed? | Yes, Prestige Biologics is a public company listed on Korea Exchange. |
| What is the stock symbol of Prestige Biologics? | Prestige Biologics trades under 334970 ticker. |
| When did Prestige Biologics go public? | Prestige Biologics went public in 2021. |
| Who are competitors of Prestige Biologics? | Prestige Biologics main competitors are AN2 Therapeutics, Oncolytics Biotech, Equillium, Immunic. |
| What is the current market cap of Prestige Biologics? | Prestige Biologics' current market cap is $130M. |
| What is the current revenue of Prestige Biologics? | Prestige Biologics' last fiscal year revenue is $8M. |
| What is the current EV/Revenue multiple of Prestige Biologics? | Current revenue multiple of Prestige Biologics is 21.9x. |
| Is Prestige Biologics profitable? | No, Prestige Biologics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.